A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 20 Feb 2018 The trial has been suspended in Spain.
- 14 Jan 2018 This trial has been Discontinued in Poland.
- 23 Sep 2016 Status changed from not yet recruiting to recruiting.